The United States Patent and Trademark Office (USPTO) has granted patent US12582106B2 to GEMPHARMATECH CO., LTD. This patent covers a novel IL-15 humanized mouse model, which incorporates a hybrid gene structure with both human and mouse IL-15 gene segments. The patent abstract specifies that the human gene segment includes parts of exons 4 through 8, while the mouse gene segment includes exons 1 through 3. The grant also includes methods for preparing this mouse model and its specific uses, particularly in the context of disease research.

This patent grant signifies the protection of intellectual property related to a specific biotechnological tool. While it does not impose direct compliance obligations on other entities, it establishes exclusive rights for the assignee. Companies involved in pharmaceutical research, particularly those developing therapies related to IL-15 or utilizing mouse models for preclinical studies, should be aware of this patent to avoid potential infringement. The filing date for this patent was December 24, 2020, and it was granted on March 24, 2026.